Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors

Vaccine. 2009 Sep 25;27(42):5837-45. doi: 10.1016/j.vaccine.2009.07.050. Epub 2009 Aug 4.


Pre-existing immunity to human adenovirus serotype 5 (AdHu5) has been shown to suppress the immunogenicity of recombinant Ad5 (rAdHu5) vector-based vaccines for human immunodeficiency virus type 1 (HIV-1) in both preclinical studies and clinical trials. As a potential solution to this problem we developed adenovirus vaccine vectors of chimpanzee origin. In the present study we assessed the immunogenicity of various chimpanzee adenovirus vectors in a prime/boost regimen to HIV-1 envelope and SIV Gag-Pol in rhesus monkeys and their ability to protect against pathogenic viral challenge. Although rAdHu5-primed monkeys had higher magnitude T cell responses than rAdC7 or rAdC68 prior to challenge, the rAdC7-rAdC1/C5 and rAdHu5-rAdC1/C5 immunizations resulted in comparable magnitude recall cellular immune responses and comparable level of control of viremia post-challenge.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural

MeSH terms

  • AIDS Vaccines / immunology*
  • Adenoviruses, Human / immunology
  • Adenoviruses, Simian / immunology*
  • Animals
  • Antibodies, Viral / blood
  • Antibodies, Viral / immunology
  • CD4 Lymphocyte Count
  • CD4-Positive T-Lymphocytes / immunology
  • Cytokines / immunology
  • Disease Models, Animal
  • Genetic Vectors / immunology
  • HIV Infections / immunology
  • HIV Infections / prevention & control*
  • HIV-1 / immunology
  • Immunity, Cellular
  • Immunization, Secondary*
  • Macaca mulatta
  • Neutralization Tests
  • Pan troglodytes / virology
  • RNA, Viral / analysis
  • Simian Immunodeficiency Virus / immunology
  • env Gene Products, Human Immunodeficiency Virus / immunology*


  • AIDS Vaccines
  • Antibodies, Viral
  • Cytokines
  • RNA, Viral
  • env Gene Products, Human Immunodeficiency Virus